ID   FLNA_HUMAN              Reviewed;        2647 AA.
AC   P21333; E9KL45; Q5HY53; Q5HY55; Q8NF52;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   28-JUN-2023, entry version 266.
DE   RecName: Full=Filamin-A;
DE            Short=FLN-A;
DE   AltName: Full=Actin-binding protein 280;
DE            Short=ABP-280;
DE   AltName: Full=Alpha-filamin;
DE   AltName: Full=Endothelial actin-binding protein;
DE   AltName: Full=Filamin-1;
DE   AltName: Full=Non-muscle filamin;
GN   Name=FLNA; Synonyms=FLN, FLN1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=2391361; DOI=10.1083/jcb.111.3.1089;
RA   Gorlin J.B., Yamin R., Egan S., Stewart M., Stossel T.P., Kwiatkowski D.J.,
RA   Hartwig J.H.;
RT   "Human endothelial actin-binding protein (ABP-280, nonmuscle filamin): a
RT   molecular leaf spring.";
RL   J. Cell Biol. 111:1089-1105(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8088819; DOI=10.1006/geno.1994.1226;
RA   Patrosso M.C., Repetto M., Villa A., Milanesi L., Frattini A., Faranda S.,
RA   Mancini M., Maestrini E., Toniolo D., Vezzoni P.;
RT   "The exon-intron organization of the human X-linked gene (FLN1) encoding
RT   actin-binding protein 280.";
RL   Genomics 21:71-76(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8733135; DOI=10.1093/hmg/5.5.659;
RA   Chen E.Y., Zollo M., Mazzarella R.A., Ciccodicola A., Chen C.-N., Zuo L.,
RA   Heiner C., Burough F.W., Ripetto M., Schlessinger D., D'Urso M.;
RT   "Long-range sequence analysis in Xq28: thirteen known and six candidate
RT   genes in 219.4 kb of high GC DNA between the RCP/GCP and G6PD loci.";
RL   Hum. Mol. Genet. 5:659-668(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=20736409; DOI=10.1074/mcp.m110.001719;
RA   Li J., Liu F., Wang H., Liu X., Liu J., Li N., Wan F., Wang W., Zhang C.,
RA   Jin S., Liu J., Zhu P., Liu Y.;
RT   "Systematic mapping and functional analysis of a family of human epididymal
RT   secretory sperm-located proteins.";
RL   Mol. Cell. Proteomics 9:2517-2528(2010).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Spleen;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=21697133; DOI=10.1167/iovs.11-7479;
RA   Oshikawa M., Tsutsui C., Ikegami T., Fuchida Y., Matsubara M., Toyama S.,
RA   Usami R., Ohtoko K., Kato S.;
RT   "Full-length transcriptome analysis of human retina-derived cell lines
RT   ARPE-19 and Y79 using the vector-capping method.";
RL   Invest. Ophthalmol. Vis. Sci. 52:6662-6670(2011).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   PROTEIN SEQUENCE OF 2-24; 44-51; 64-87; 101-127; 172-190; 300-376; 384-400;
RP   428-437; 497-504; 581-593; 656-664; 685-700; 761-771; 774-781; 829-837;
RP   842-900; 907-916; 959-973; 983-994; 1020-1032; 1165-1172; 1235-1294;
RP   1297-1312; 1360-1399; 1440-1450; 1465-1486; 1492-1532; 1539-1547;
RP   1550-1592; 1622-1633; 1636-1644; 1726-1753; 1801-1809; 1815-1831;
RP   1892-1907; 1965-1993; 2015-2024; 2026-2049; 2202-2215; 2243-2250;
RP   2265-2289; 2311-2333; 2335-2361; 2396-2405; 2521-2540; 2585-2598 AND
RP   2613-2631, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT SER-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Platelet;
RA   Bienvenut W.V., Claeys D.;
RL   Submitted (NOV-2005) to UniProtKB.
RN   [10]
RP   PROTEIN SEQUENCE OF 25-54; 917-940; 1037-1050; 1754-1783 AND 2148-2168.
RX   PubMed=2248958; DOI=10.1021/bi00492a019;
RA   Hock R.S., Davis G., Speicher D.W.;
RT   "Purification of human smooth muscle filamin and characterization of
RT   structural domains and functional sites.";
RL   Biochemistry 29:9441-9451(1990).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1658-1772.
RX   PubMed=7689010; DOI=10.1093/hmg/2.6.761;
RA   Maestrini E., Patrosso C., Mancini M., Rivella S., Rocchi M., Repetto M.,
RA   Villa A., Frattini A., Zoppe M., Vezzoni P., Toniolo D.;
RT   "Mapping of two genes encoding isoforms of the actin binding protein ABP-
RT   280, a dystrophin like protein, to Xq28 and to chromosome 7.";
RL   Hum. Mol. Genet. 2:761-766(1993).
RN   [12]
RP   SIMILARITY TO OTHER MEMBERS OF THE FAMILY.
RX   PubMed=11153914; DOI=10.1007/s004390000414;
RA   Chakarova C., Wehnert M.S., Uhl K., Sakthivel S., Vosberg H.-P.,
RA   van der Ven P.F.M., Fuerst D.O.;
RT   "Genomic structure and fine mapping of the two human filamin gene
RT   paralogues FLNB and FLNC and comparative analysis of the filamin gene
RT   family.";
RL   Hum. Genet. 107:597-611(2000).
RN   [13]
RP   INTERACTION WITH PSEN1 AND PSEN2.
RX   PubMed=9437013; DOI=10.1523/jneurosci.18-03-00914.1998;
RA   Zhang W., Han S.W., McKeel D.W., Goate A., Wu J.Y.;
RT   "Interaction of presenilins with the filamin family of actin-binding
RT   proteins.";
RL   J. Neurosci. 18:914-922(1998).
RN   [14]
RP   INTERACTION WITH KCND2.
RX   PubMed=11102480; DOI=10.1523/jneurosci.20-23-08736.2000;
RA   Petrecca K., Miller D.M., Shrier A.;
RT   "Localization and enhanced current density of the Kv4.2 potassium channel
RT   by interaction with the actin-binding protein filamin.";
RL   J. Neurosci. 20:8736-8744(2000).
RN   [15]
RP   INTERACTION WITH INPPL1.
RX   PubMed=11739414; DOI=10.1083/jcb.200104005;
RA   Dyson J.M., O'Malley C.J., Becanovic J., Munday A.D., Berndt M.C.,
RA   Coghill I.D., Nandurkar H.H., Ooms L.M., Mitchell C.A.;
RT   "The SH2-containing inositol polyphosphate 5-phosphatase, SHIP-2, binds
RT   filamin and regulates submembraneous actin.";
RL   J. Cell Biol. 155:1065-1079(2001).
RN   [16]
RP   INTERACTION WITH FLNB.
RX   PubMed=12393796; DOI=10.1093/hmg/11.23.2845;
RA   Sheen V.L., Feng Y., Graham D., Takafuta T., Shapiro S.S., Walsh C.A.;
RT   "Filamin A and filamin B are co-expressed within neurons during periods of
RT   neuronal migration and can physically interact.";
RL   Hum. Mol. Genet. 11:2845-2854(2002).
RN   [17]
RP   INTERACTION WITH MYOT AND MYOZ1.
RX   PubMed=16076904; DOI=10.1242/jcs.02484;
RA   Gontier Y., Taivainen A., Fontao L., Sonnenberg A., van der Flier A.,
RA   Carpen O., Faulkner G., Borradori L.;
RT   "The Z-disc proteins myotilin and FATZ-1 interact with each other and are
RT   connected to the sarcolemma via muscle-specific filamins.";
RL   J. Cell Sci. 118:3739-3749(2005).
RN   [18]
RP   REVIEW.
RX   PubMed=11336782; DOI=10.1016/s0167-4889(01)00072-6;
RA   van der Flier A., Sonnenberg A.;
RT   "Structural and functional aspects of filamins.";
RL   Biochim. Biophys. Acta 1538:99-117(2001).
RN   [19]
RP   REVIEW.
RX   PubMed=11252955; DOI=10.1038/35052082;
RA   Stossel T.P., Condeelis J., Cooley L., Hartwig J.H., Noegel A.,
RA   Schleicher M., Shapiro S.S.;
RT   "Filamins as integrators of cell mechanics and signalling.";
RL   Nat. Rev. Mol. Cell Biol. 2:138-145(2001).
RN   [20]
RP   INTERACTION WITH CEACAM1, AND SUBCELLULAR LOCATION.
RX   PubMed=16291724; DOI=10.1242/jcs.02660;
RA   Klaile E., Mueller M.M., Kannicht C., Singer B.B., Lucka L.;
RT   "CEACAM1 functionally interacts with filamin A and exerts a dual role in
RT   the regulation of cell migration.";
RL   J. Cell Sci. 118:5513-5524(2005).
RN   [21]
RP   INTERACTION WITH FOXC1.
RX   PubMed=15684392; DOI=10.1128/mcb.25.4.1415-1424.2005;
RA   Berry F.B., O'Neill M.A., Coca-Prados M., Walter M.A.;
RT   "FOXC1 transcriptional regulatory activity is impaired by PBX1 in a filamin
RT   A-mediated manner.";
RL   Mol. Cell. Biol. 25:1415-1424(2005).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1089; SER-1459; SER-2152 AND
RP   SER-2284, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [23]
RP   INVOLVEMENT IN PVNH1.
RX   PubMed=16299064; DOI=10.1136/jmg.2005.038505;
RA   Hehr U., Hehr A., Uyanik G., Phelan E., Winkler J., Reardon W.;
RT   "A filamin A splice mutation resulting in a syndrome of facial dysmorphism,
RT   periventricular nodular heterotopia, and severe constipation reminiscent of
RT   cerebro-fronto-facial syndrome.";
RL   J. Med. Genet. 43:541-544(2006).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1084 AND SER-1459, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [25]
RP   INTERACTION WITH ARHGAP24.
RX   PubMed=16862148; DOI=10.1038/ncb1437;
RA   Ohta Y., Hartwig J.H., Stossel T.P.;
RT   "FilGAP, a Rho- and ROCK-regulated GAP for Rac binds filamin A to control
RT   actin remodelling.";
RL   Nat. Cell Biol. 8:803-814(2006).
RN   [26]
RP   INVOLVEMENT IN IPOX.
RX   PubMed=17357080; DOI=10.1086/513321;
RA   Gargiulo A., Auricchio R., Barone M.V., Cotugno G., Reardon W., Milla P.J.,
RA   Ballabio A., Ciccodicola A., Auricchio A.;
RT   "Filamin A is mutated in X-linked chronic idiopathic intestinal pseudo-
RT   obstruction with central nervous system involvement.";
RL   Am. J. Hum. Genet. 80:751-758(2007).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1084, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa cells
RT   and high confident phosphopeptide identification by cross-validation of
RT   MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [28]
RP   INTERACTION WITH ECSCR.
RX   PubMed=18556573; DOI=10.1161/atvbaha.108.162511;
RA   Armstrong L.-J., Heath V.L., Sanderson S., Kaur S., Beesley J.F.J.,
RA   Herbert J.M.J., Legg J.A., Poulsom R., Bicknell R.;
RT   "ECSM2, an endothelial specific filamin a binding protein that mediates
RT   chemotaxis.";
RL   Arterioscler. Thromb. Vasc. Biol. 28:1640-1646(2008).
RN   [29]
RP   INTERACTION WITH FCGR1A.
RX   PubMed=18322202; DOI=10.4049/jimmunol.180.6.3938;
RA   Beekman J.M., van der Poel C.E., van der Linden J.A., van den Berg D.L.C.,
RA   van den Berghe P.V.E., van de Winkel J.G.J., Leusen J.H.W.;
RT   "Filamin A stabilizes FcgammaRI surface expression and prevents its
RT   lysosomal routing.";
RL   J. Immunol. 180:3938-3945(2008).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1084, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1459, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using sequential
RT   IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1084; SER-1459; SER-2152 AND
RP   SER-2158, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1081, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1084; SER-1338; SER-1459;
RP   SER-1533; SER-1630; SER-2053; SER-2152; SER-2327; SER-2414 AND SER-2510,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [35]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [36]
RP   INTERACTION WITH GP1BA; ITGB7; ITGB2 AND FBLIM1.
RX   PubMed=19828450; DOI=10.1074/jbc.m109.060954;
RA   Ithychanda S.S., Hsu D., Li H., Yan L., Liu D.D., Liu D., Das M.,
RA   Plow E.F., Qin J.;
RT   "Identification and characterization of multiple similar ligand-binding
RT   repeats in filamin: implication on filamin-mediated receptor clustering and
RT   cross-talk.";
RL   J. Biol. Chem. 284:35113-35121(2009).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1084, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [38]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-508; LYS-700; LYS-781; LYS-837;
RP   LYS-2607 AND LYS-2621, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [39]
RP   INTERACTION WITH SYK.
RX   PubMed=20713593; DOI=10.1084/jem.20100222;
RA   Falet H., Pollitt A.Y., Begonja A.J., Weber S.E., Duerschmied D.,
RA   Wagner D.D., Watson S.P., Hartwig J.H.;
RT   "A novel interaction between FlnA and Syk regulates platelet ITAM-mediated
RT   receptor signaling and function.";
RL   J. Exp. Med. 207:1967-1979(2010).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1081; SER-1084; SER-1459;
RP   SER-1533; SER-1734; SER-2053; SER-2152; SER-2284; SER-2327; THR-2336 AND
RP   SER-2414, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [41]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [42]
RP   INTERACTION WITH ITGB7 AND FBLIM1, AND DOMAIN.
RX   PubMed=21524097; DOI=10.1021/bi2003229;
RA   Ithychanda S.S., Qin J.;
RT   "Evidence for multisite ligand binding and stretching of filamin by
RT   integrin and migfilin.";
RL   Biochemistry 50:4229-4231(2011).
RN   [43]
RP   INTERACTION WITH TAF1B AND MIS18BP1, AND CHARACTERIZATION OF VARIANTS
RP   ALA-1159; THR-1188 AND LEU-1199.
RX   PubMed=21228480; DOI=10.1271/bbb.100567;
RA   Qiu H., Nomiyama R., Moriguchi K., Fukada T., Sugimoto K.;
RT   "Identification of novel nuclear protein interactions with the N-terminal
RT   part of filamin A.";
RL   Biosci. Biotechnol. Biochem. 75:145-147(2011).
RN   [44]
RP   INVOLVEMENT IN MACROTHROMBOCYTOPENIA, AND VARIANT LYS-1803.
RX   PubMed=21960593; DOI=10.1182/blood-2011-07-365601;
RA   Nurden P., Debili N., Coupry I., Bryckaert M., Youlyouz-Marfak I., Sole G.,
RA   Pons A.C., Berrou E., Adam F., Kauskot A., Lamaziere J.M., Rameau P.,
RA   Fergelot P., Rooryck C., Cailley D., Arveiler B., Lacombe D.,
RA   Vainchenker W., Nurden A., Goizet C.;
RT   "Thrombocytopenia resulting from mutations in filamin A can be expressed as
RT   an isolated syndrome.";
RL   Blood 118:5928-5937(2011).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; SER-1081; SER-1084;
RP   SER-1459; SER-2152 AND SER-2327, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [46]
RP   FUNCTION IN CILIOGENESIS, AND INTERACTION WITH TMEM67 AND MKS1.
RX   PubMed=22121117; DOI=10.1093/hmg/ddr557;
RA   Adams M., Simms R.J., Abdelhamed Z., Dawe H.R., Szymanska K., Logan C.V.,
RA   Wheway G., Pitt E., Gull K., Knowles M.A., Blair E., Cross S.H.,
RA   Sayer J.A., Johnson C.A.;
RT   "A meckelin-filamin A interaction mediates ciliogenesis.";
RL   Hum. Mol. Genet. 21:1272-1286(2012).
RN   [47]
RP   INTERACTION WITH MICALL2.
RX   PubMed=23890175; DOI=10.1111/gtc.12078;
RA   Sakane A., Alamir Mahmoud Abdallah A., Nakano K., Honda K., Kitamura T.,
RA   Imoto I., Matsushita N., Sasaki T.;
RT   "Junctional Rab13-binding protein (JRAB) regulates cell spreading via
RT   filamins.";
RL   Genes Cells 18:810-822(2013).
RN   [48]
RP   INVOLVEMENT IN CSBSX.
RX   PubMed=23037936; DOI=10.1038/gim.2012.123;
RA   van der Werf C.S., Sribudiani Y., Verheij J.B., Carroll M., O'Loughlin E.,
RA   Chen C.H., Brooks A.S., Liszewski M.K., Atkinson J.P., Hofstra R.M.;
RT   "Congenital short bowel syndrome as the presenting symptom in male patients
RT   with FLNA mutations.";
RL   Genet. Med. 15:310-313(2013).
RN   [49]
RP   UBIQUITINATION AT LYS-42; LYS-43 AND LYS-135, AND MUTAGENESIS OF LYS-42;
RP   LYS-43 AND LYS-135.
RX   PubMed=24052262; DOI=10.1074/jbc.m113.496604;
RA   Razinia Z., Baldassarre M., Cantelli G., Calderwood D.A.;
RT   "ASB2alpha, an E3 ubiquitin ligase specificity subunit, regulates cell
RT   spreading and triggers proteasomal degradation of filamins by targeting the
RT   filamin calponin homology 1 domain.";
RL   J. Biol. Chem. 288:32093-32105(2013).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1081; SER-1084; SER-1301;
RP   SER-1459; SER-1533; SER-1630; SER-1835; SER-2128; SER-2152; SER-2158;
RP   SER-2284; SER-2327; THR-2336; SER-2338 AND SER-2510, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1055; SER-1081; SER-1459;
RP   SER-1734; SER-1967; SER-2152; SER-2158 AND SER-2163, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [52]
RP   FUNCTION, AND INTERACTION WITH CRMP1; DPYSL3 AND DPYSL4.
RX   PubMed=25358863; DOI=10.1038/ncomms6325;
RA   Nakamura F., Kumeta K., Hida T., Isono T., Nakayama Y.,
RA   Kuramata-Matsuoka E., Yamashita N., Uchida Y., Ogura K., Gengyo-Ando K.,
RA   Mitani S., Ogino T., Goshima Y.;
RT   "Amino- and carboxyl-terminal domains of Filamin-A interact with CRMP1 to
RT   mediate Sema3A signalling.";
RL   Nat. Commun. 5:5325-5325(2014).
RN   [53]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-299, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [54]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-299, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [55]
RP   INTERACTION WITH DRD3; MAS1; AGTR1 AND ADRA1D, AND PHOSPHORYLATION AT
RP   SER-2152.
RX   PubMed=26460884; DOI=10.1021/acs.biochem.5b00975;
RA   Tirupula K.C., Ithychanda S.S., Mohan M.L., Naga Prasad S.V., Qin J.,
RA   Karnik S.S.;
RT   "G Protein-Coupled Receptors Directly Bind Filamin A with High Affinity and
RT   Promote Filamin Phosphorylation.";
RL   Biochemistry 54:6673-6683(2015).
RN   [56]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-299, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [57]
RP   PHOSPHORYLATION AT SER-2152 AND THR-2336, REGULATION OF PHOSPHORYLATION AT
RP   SER-2152, INTERACTION WITH GP1BA, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=25666618; DOI=10.1074/jbc.m114.633446;
RA   Ithychanda S.S., Fang X., Mohan M.L., Zhu L., Tirupula K.C.,
RA   Naga Prasad S.V., Wang Y.X., Karnik S.S., Qin J.;
RT   "A mechanism of global shape-dependent recognition and phosphorylation of
RT   filamin by protein kinase A.";
RL   J. Biol. Chem. 290:8527-8538(2015).
RN   [58]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-299, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [59]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [60]
RP   UBIQUITINATION.
RX   PubMed=26766444; DOI=10.1016/j.devcel.2015.12.015;
RA   Scholz B., Korn C., Wojtarowicz J., Mogler C., Augustin I., Boutros M.,
RA   Niehrs C., Augustin H.G.;
RT   "Endothelial RSPO3 controls vascular stability and pruning through non-
RT   canonical WNT/Ca(2+)/NFAT signaling.";
RL   Dev. Cell 36:79-93(2016).
RN   [61]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-299, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [62]
RP   VARIANT LEU-606.
RX   PubMed=30500825; DOI=10.1371/journal.pgen.1007671;
RA   Hiatt S.M., Neu M.B., Ramaker R.C., Hardigan A.A., Prokop J.W.,
RA   Hancarova M., Prchalova D., Havlovicova M., Prchal J., Stranecky V.,
RA   Yim D.K.C., Powis Z., Keren B., Nava C., Mignot C., Rio M.,
RA   Revah-Politi A., Hemati P., Stong N., Iglesias A.D., Suchy S.F.,
RA   Willaert R., Wentzensen I.M., Wheeler P.G., Brick L., Kozenko M.,
RA   Hurst A.C.E., Wheless J.W., Lacassie Y., Myers R.M., Barsh G.S.,
RA   Sedlacek Z., Cooper G.M.;
RT   "De novo mutations in the GTP/GDP-binding region of RALA, a RAS-like small
RT   GTPase, cause intellectual disability and developmental delay.";
RL   PLoS Genet. 14:e1007671-e1007671(2018).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 2045-2329, AND DOMAIN.
RX   PubMed=17690686; DOI=10.1038/sj.emboj.7601827;
RA   Lad Y., Kiema T., Jiang P., Pentikainen O.T., Coles C.H., Campbell I.D.,
RA   Calderwood D.A., Ylanne J.;
RT   "Structure of three tandem filamin domains reveals auto-inhibition of
RT   ligand binding.";
RL   EMBO J. 26:3993-4004(2007).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 1-278, ACTIN-BINDING REGION, AND
RP   SUBUNIT.
RX   PubMed=19923718; DOI=10.1107/s0907444909037330;
RA   Ruskamo S., Ylanne J.;
RT   "Structure of the human filamin A actin-binding domain.";
RL   Acta Crystallogr. D 65:1217-1221(2009).
RN   [65]
RP   STRUCTURE BY NMR OF 1772-1956 AND 1954-2141.
RX   PubMed=19622754; DOI=10.1074/jbc.m109.019661;
RA   Heikkinen O.K., Ruskamo S., Konarev P.V., Svergun D.I., Iivanainen T.,
RA   Heikkinen S.M., Permi P., Koskela H., Kilpelainen I., Ylanne J.;
RT   "Atomic structures of two novel immunoglobulin-like domain pairs in the
RT   actin cross-linking protein filamin.";
RL   J. Biol. Chem. 284:25450-25458(2009).
RN   [66]
RP   VARIANT PVNH1 PHE-656, AND VARIANT THR-1764.
RX   PubMed=11532987; DOI=10.1093/hmg/10.17.1775;
RA   Sheen V.L., Dixon P.H., Fox J.W., Hong S.E., Kinton L., Sisodiya S.M.,
RA   Duncan J.S., Dubeau F., Scheffer I.E., Schachter S.C., Wilner A.,
RA   Henchy R., Crino P., Kamuro K., DiMario F., Berg M., Kuzniecky R.,
RA   Cole A.J., Bromfield E., Biber M., Schomer D., Wheless J., Silver K.,
RA   Mochida G.H., Berkovic S.F., Andermann F., Andermann E., Dobyns W.B.,
RA   Wood N.W., Walsh C.A.;
RT   "Mutations in the X-linked filamin 1 gene cause periventricular nodular
RT   heterotopia in males as well as in females.";
RL   Hum. Mol. Genet. 10:1775-1783(2001).
RN   [67]
RP   VARIANT MET-528.
RX   PubMed=12410386; DOI=10.1007/s00401-002-0594-9;
RA   Kakita A., Hayashi S., Moro F., Guerrini R., Ozawa T., Ono K., Kameyama S.,
RA   Walsh C.A., Takahashi H.;
RT   "Bilateral periventricular nodular heterotopia due to filamin 1 gene
RT   mutation: widespread glomeruloid microvascular anomaly and dysplastic
RT   cytoarchitecture in the cerebral cortex.";
RL   Acta Neuropathol. 104:649-657(2002).
RN   [68]
RP   VARIANT PVNH1 VAL-82.
RX   PubMed=11914408; DOI=10.1212/wnl.58.6.916;
RA   Moro F., Carrozzo R., Veggiotti P., Tortorella G., Toniolo D., Volzone A.,
RA   Guerrini R.;
RT   "Familial periventricular heterotopia: missense and distal truncating
RT   mutations of the FLN1 gene.";
RL   Neurology 58:916-921(2002).
RN   [69]
RP   VARIANTS OPD1 PHE-172; TRP-196 AND LEU-207, VARIANTS OPD2 PRO-170; GLY-196;
RP   SER-200; LYS-254; PRO-273; LYS-555 AND PHE-1645, VARIANTS FMD1 ALA-1159;
RP   LEU-1186 AND ILE-1620 DEL, VARIANTS MNS GLU-1184; THR-1188 AND LEU-1199,
RP   AND VARIANTS MET-429 AND THR-1764.
RX   PubMed=12612583; DOI=10.1038/ng1119;
RA   Robertson S.P., Twigg S.R.F., Sutherland-Smith A.J., Biancalana V.,
RA   Gorlin R.J., Horn D., Kenwrick S.J., Kim C.A., Morava E., Newbury-Ecob R.,
RA   Oerstavik K.H., Quarrell O.W.J., Schwartz C.E., Shears D.J., Suri M.,
RA   Kendrick-Jones J., Wilkie A.O.M.;
RT   "Localized mutations in the gene encoding the cytoskeletal protein filamin
RT   A cause diverse malformations in humans.";
RL   Nat. Genet. 33:487-491(2003).
RN   [70]
RP   VARIANTS PVNH1 VAL-102 AND PHE-149.
RX   PubMed=15249610; DOI=10.1212/01.wnl.0000132818.84827.4d;
RA   Guerrini R., Mei D., Sisodiya S.M., Sicca F., Harding B., Takahashi Y.,
RA   Dorn T., Yoshida A., Campistol J., Kraemer G., Moro F., Dobyns W.B.,
RA   Parrini E.;
RT   "Germline and mosaic mutations of FLN1 in men with periventricular
RT   heterotopia.";
RL   Neurology 63:51-56(2004).
RN   [71]
RP   VARIANT OTOPALATODIGITAL SPECTRUM DISORDER 1635-ARG--VAL-1637 DEL.
RX   PubMed=15654694; DOI=10.1002/ajmg.a.30484;
RA   Stefanova M., Meinecke P., Gal A., Bolz H.;
RT   "A novel 9 bp deletion in the filamin A gene causes an otopalatodigital-
RT   spectrum disorder with a variable, intermediate phenotype.";
RL   Am. J. Med. Genet. A 132:386-390(2005).
RN   [72]
RP   VARIANT OPD1 TYR-203.
RX   PubMed=15940695; DOI=10.1002/ajmg.a.30792;
RA   Hidalgo-Bravo A., Pompa-Mera E.N., Kofman-Alfaro S., Gonzalez-Bonilla C.R.,
RA   Zenteno J.C.;
RT   "A novel filamin A D203Y mutation in a female patient with otopalatodigital
RT   type 1 syndrome and extremely skewed X chromosome inactivation.";
RL   Am. J. Med. Genet. A 136:190-193(2005).
RN   [73]
RP   VARIANT PVNH1 GLY-39.
RX   PubMed=15668422; DOI=10.1212/01.wnl.0000149512.79621.df;
RA   Sheen V.L., Jansen A., Chen M.H., Parrini E., Morgan T., Ravenscroft R.,
RA   Ganesh V., Underwood T., Wiley J., Leventer R., Vaid R.R., Ruiz D.E.,
RA   Hutchins G.M., Menasha J., Willner J., Geng Y., Gripp K.W., Nicholson L.,
RA   Berry-Kravis E., Bodell A., Apse K., Hill R.S., Dubeau F., Andermann F.,
RA   Barkovich J., Andermann E., Shugart Y.Y., Thomas P., Viri M., Veggiotti P.,
RA   Robertson S., Guerrini R., Walsh C.A.;
RT   "Filamin A mutations cause periventricular heterotopia with Ehlers-Danlos
RT   syndrome.";
RL   Neurology 64:254-262(2005).
RN   [74]
RP   VARIANTS FMD1 LEU-1186 AND CYS-1728.
RX   PubMed=16596676; DOI=10.1002/ajmg.a.31213;
RA   Zenker M., Naehrlich L., Sticht H., Reis A., Horn D.;
RT   "Genotype-epigenotype-phenotype correlations in females with
RT   frontometaphyseal dysplasia.";
RL   Am. J. Med. Genet. A 140:1069-1073(2006).
RN   [75]
RP   VARIANT PVNH1 VAL-128.
RX   PubMed=15994863; DOI=10.1136/jmg.2004.029173;
RA   Gomez-Garre P., Seijo M., Gutierrez-Delicado E., Castro del Rio M.,
RA   de la Torre C., Gomez-Abad C., Morales-Corraliza J., Puig M.,
RA   Serratosa J.M.;
RT   "Ehlers-Danlos syndrome and periventricular nodular heterotopia in a
RT   Spanish family with a single FLNA mutation.";
RL   J. Med. Genet. 43:232-237(2006).
RN   [76]
RP   VARIANT OPD2 PHE-210.
RX   PubMed=17431908; DOI=10.1002/ajmg.a.31696;
RA   Marino-Enriquez A., Lapunzina P., Robertson S.P., Rodriguez J.I.;
RT   "Otopalatodigital syndrome type 2 in two siblings with a novel filamin A
RT   629G>T mutation: clinical, pathological, and molecular findings.";
RL   Am. J. Med. Genet. A 143:1120-1125(2007).
RN   [77]
RP   VARIANT FGS2 LEU-1291.
RX   PubMed=17632775; DOI=10.1002/ajmg.a.31751;
RA   Unger S., Mainberger A., Spitz C., Baehr A., Zeschnigk C., Zabel B.,
RA   Superti-Furga A., Morris-Rosendahl D.J.;
RT   "Filamin A mutation is one cause of FG syndrome.";
RL   Am. J. Med. Genet. A 143:1876-1879(2007).
RN   [78]
RP   VARIANTS CVDPX ARG-288; GLN-637 AND ASP-711.
RX   PubMed=17190868; DOI=10.1161/circulationaha.106.622621;
RA   Kyndt F., Gueffet J.P., Probst V., Jaafar P., Legendre A., Le Bouffant F.,
RA   Toquet C., Roy E., McGregor L., Lynch S.A., Newbury-Ecob R., Tran V.,
RA   Young I., Trochu J.N., Le Marec H., Schott J.J.;
RT   "Mutations in the gene encoding filamin A as a cause for familial cardiac
RT   valvular dystrophy.";
RL   Circulation 115:40-49(2007).
RN   [79]
RP   VARIANT TOD 1724-VAL--THR-1739 DEL.
RX   PubMed=20598277; DOI=10.1016/j.ajhg.2010.06.008;
RA   Sun Y., Almomani R., Aten E., Celli J., van der Heijden J., Venselaar H.,
RA   Robertson S.P., Baroncini A., Franco B., Basel-Vanagaite L., Horii E.,
RA   Drut R., Ariyurek Y., den Dunnen J.T., Breuning M.H.;
RT   "Terminal osseous dysplasia is caused by a single recurrent mutation in the
RT   FLNA gene.";
RL   Am. J. Hum. Genet. 87:146-153(2010).
RN   [80]
RP   VARIANT MET-528.
RX   PubMed=20844545; DOI=10.1038/jhg.2010.114;
RA   Kunishima S., Ito-Yamamura Y., Hayakawa A., Yamamoto T., Saito H.;
RT   "FLNA p.V528M substitution is neither associated with bilateral
RT   periventricular nodular heterotopia nor with macrothrombocytopenia.";
RL   J. Hum. Genet. 55:844-846(2010).
RN   [81]
RP   VARIANTS OPD2 SER-187 AND GLY-196, VARIANTS OPD1 LEU-207; THR-267; ASP-804
RP   AND HIS-2391, VARIANTS FMD1 VAL-1142; LEU-1186 AND ARG-1840, AND VARIANTS
RP   MNS LEU-1163 AND THR-1188.
RX   PubMed=27193221; DOI=10.1038/jhg.2016.37;
RA   Moutton S., Fergelot P., Naudion S., Cordier M.P., Sole G., Guerineau E.,
RA   Hubert C., Rooryck C., Vuillaume M.L., Houcinat N., Deforges J., Bouron J.,
RA   Deves S., Le Merrer M., David A., Genevieve D., Giuliano F., Journel H.,
RA   Megarbane A., Faivre L., Chassaing N., Francannet C., Sarrazin E.,
RA   Stattin E.L., Vigneron J., Leclair D., Abadie C., Sarda P., Baumann C.,
RA   Delrue M.A., Arveiler B., Lacombe D., Goizet C., Coupry I.;
RT   "Otopalatodigital spectrum disorders: refinement of the phenotypic and
RT   mutational spectrum.";
RL   J. Hum. Genet. 61:693-699(2016).
CC   -!- FUNCTION: Promotes orthogonal branching of actin filaments and links
CC       actin filaments to membrane glycoproteins. Anchors various
CC       transmembrane proteins to the actin cytoskeleton and serves as a
CC       scaffold for a wide range of cytoplasmic signaling proteins.
CC       Interaction with FLNB may allow neuroblast migration from the
CC       ventricular zone into the cortical plate. Tethers cell surface-
CC       localized furin, modulates its rate of internalization and directs its
CC       intracellular trafficking (By similarity). Involved in ciliogenesis.
CC       Plays a role in cell-cell contacts and adherens junctions during the
CC       development of blood vessels, heart and brain organs. Plays a role in
CC       platelets morphology through interaction with SYK that regulates
CC       ITAM- and ITAM-like-containing receptor signaling, resulting in by
CC       platelet cytoskeleton organization maintenance (By similarity). During
CC       the axon guidance process, required for growth cone collapse induced by
CC       SEMA3A-mediated stimulation of neurons (PubMed:25358863). {ECO:0000250,
CC       ECO:0000250|UniProtKB:Q8BTM8, ECO:0000269|PubMed:22121117,
CC       ECO:0000269|PubMed:25358863}.
CC   -!- SUBUNIT: Homodimer. Interacts with PDLIM2 (By similarity). Interacts
CC       with RFLNA and RFLNB (By similarity). Interacts with FCGR1A, FLNB,
CC       FURIN, HSPB7, INPPL1, KCND2, MYOT, MYOZ1, ARHGAP24, PSEN1, PSEN2 and
CC       ECSCR. Interacts also with various other binding partners in addition
CC       to filamentous actin. Interacts (via N-terminus) with MIS18BP1 (via N-
CC       terminus). Interacts (via N-terminus) with TAF1B. Interacts with TMEM67
CC       (via C-terminus) and MKS1. Interacts (via actin-binding domain) with
CC       MICALL2 (via CH domain). Interacts (via filamin repeat 5) with SYK;
CC       docks SYK to the plasma membrane (PubMed:20713593). Interacts (via
CC       filamin repeats 19 and 21) with DRD3; increased PKA-mediated
CC       phosphorylation at Ser-2152. Interacts (via filamin repeat 21) with
CC       MAS1, AGTR1 and ADRA1D; increases PKA-mediated phosphorylation of FLNA
CC       at Ser-2152 (PubMed:26460884). Interacts (via filamin repeats 4, 9, 12,
CC       17, 19, 21, and 23) with GP1BA (high affinity), ITGB7, ITGB2 and FBLIM1
CC       (PubMed:19828450, PubMed:21524097, PubMed:25666618). Interacts with
CC       CEACAM1 (via cytoplasmic domain); inhibits cell migration and cell
CC       scattering by interfering with the interaction between FLNA and RALA
CC       (PubMed:16291724). Interacts with FOXC1 (PubMed:15684392). Interacts
CC       (via calponin-homology (CH) domain 1 and filamin repeat 24) with CRMP1;
CC       the interaction alters FLNA ternary structure and thus promotes FLNA
CC       dissociation from F-actin (PubMed:25358863). Interacts with
CC       DPYSL3/CRMP3 and DPYSL4/CRMP4 (PubMed:25358863). {ECO:0000250,
CC       ECO:0000250|UniProtKB:Q8BTM8, ECO:0000269|PubMed:11102480,
CC       ECO:0000269|PubMed:11739414, ECO:0000269|PubMed:12393796,
CC       ECO:0000269|PubMed:15684392, ECO:0000269|PubMed:16076904,
CC       ECO:0000269|PubMed:16291724, ECO:0000269|PubMed:16862148,
CC       ECO:0000269|PubMed:18322202, ECO:0000269|PubMed:18556573,
CC       ECO:0000269|PubMed:19828450, ECO:0000269|PubMed:19923718,
CC       ECO:0000269|PubMed:20713593, ECO:0000269|PubMed:21228480,
CC       ECO:0000269|PubMed:21524097, ECO:0000269|PubMed:22121117,
CC       ECO:0000269|PubMed:23890175, ECO:0000269|PubMed:25358863,
CC       ECO:0000269|PubMed:25666618, ECO:0000269|PubMed:26460884,
CC       ECO:0000269|PubMed:9437013}.
CC   -!- INTERACTION:
CC       P21333; Q8N264: ARHGAP24; NbExp=6; IntAct=EBI-350432, EBI-988764;
CC       P21333; O95067: CCNB2; NbExp=8; IntAct=EBI-350432, EBI-375024;
CC       P21333; P46108: CRK; NbExp=3; IntAct=EBI-350432, EBI-886;
CC       P21333; O75369: FLNB; NbExp=5; IntAct=EBI-350432, EBI-352089;
CC       P21333; Q12948: FOXC1; NbExp=8; IntAct=EBI-350432, EBI-1175253;
CC       P21333; P51114: FXR1; NbExp=2; IntAct=EBI-350432, EBI-713291;
CC       P21333; P62993: GRB2; NbExp=2; IntAct=EBI-350432, EBI-401755;
CC       P21333; P08514-1: ITGA2B; NbExp=3; IntAct=EBI-350432, EBI-15805658;
CC       P21333; P05556: ITGB1; NbExp=5; IntAct=EBI-350432, EBI-703066;
CC       P21333; P05106: ITGB3; NbExp=3; IntAct=EBI-350432, EBI-702847;
CC       P21333; P26010: ITGB7; NbExp=6; IntAct=EBI-350432, EBI-702932;
CC       P21333; P26010-1: ITGB7; NbExp=2; IntAct=EBI-350432, EBI-15944630;
CC       P21333; O14786: NRP1; NbExp=2; IntAct=EBI-350432, EBI-1187100;
CC       P21333; P35372: OPRM1; NbExp=5; IntAct=EBI-350432, EBI-2624570;
CC       P21333; Q86SQ0: PHLDB2; NbExp=3; IntAct=EBI-350432, EBI-2798483;
CC       P21333; Q9BYB0: SHANK3; NbExp=2; IntAct=EBI-350432, EBI-1752330;
CC       P21333; P07228: ITGB1; Xeno; NbExp=2; IntAct=EBI-350432, EBI-5606437;
CC       P21333; PRO_0000037548 [Q9WMX2]; Xeno; NbExp=6; IntAct=EBI-350432, EBI-6863741;
CC       P21333; PRO_0000037551 [Q9WMX2]; Xeno; NbExp=6; IntAct=EBI-350432, EBI-6863748;
CC       P21333-2; Q6UY14-3: ADAMTSL4; NbExp=6; IntAct=EBI-9641086, EBI-10173507;
CC       P21333-2; P05067: APP; NbExp=3; IntAct=EBI-9641086, EBI-77613;
CC       P21333-2; Q14457: BECN1; NbExp=3; IntAct=EBI-9641086, EBI-949378;
CC       P21333-2; Q96IK1-2: BOD1; NbExp=3; IntAct=EBI-9641086, EBI-18924329;
CC       P21333-2; Q9BSJ5: C17orf80; NbExp=3; IntAct=EBI-9641086, EBI-2872520;
CC       P21333-2; Q96NX5: CAMK1G; NbExp=3; IntAct=EBI-9641086, EBI-3920838;
CC       P21333-2; Q8N5S9-2: CAMKK1; NbExp=3; IntAct=EBI-9641086, EBI-25850646;
CC       P21333-2; Q6ZP82: CCDC141; NbExp=3; IntAct=EBI-9641086, EBI-928795;
CC       P21333-2; Q8IUI8: CRLF3; NbExp=3; IntAct=EBI-9641086, EBI-2872414;
CC       P21333-2; P53672: CRYBA2; NbExp=3; IntAct=EBI-9641086, EBI-750444;
CC       P21333-2; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-9641086, EBI-3867333;
CC       P21333-2; Q96D03: DDIT4L; NbExp=5; IntAct=EBI-9641086, EBI-742054;
CC       P21333-2; O00472: ELL2; NbExp=3; IntAct=EBI-9641086, EBI-395274;
CC       P21333-2; P07148: FABP1; NbExp=3; IntAct=EBI-9641086, EBI-2115989;
CC       P21333-2; Q6P1L5: FAM117B; NbExp=3; IntAct=EBI-9641086, EBI-3893327;
CC       P21333-2; Q8TAK5: GABPB2; NbExp=3; IntAct=EBI-9641086, EBI-8468945;
CC       P21333-2; F2Z2M7: GALNT10; NbExp=3; IntAct=EBI-9641086, EBI-23893155;
CC       P21333-2; Q9Y4H4: GPSM3; NbExp=3; IntAct=EBI-9641086, EBI-347538;
CC       P21333-2; Q9XRX5-2: HHLA3; NbExp=3; IntAct=EBI-9641086, EBI-12051311;
CC       P21333-2; P17066: HSPA6; NbExp=3; IntAct=EBI-9641086, EBI-355106;
CC       P21333-2; Q9UBY9: HSPB7; NbExp=10; IntAct=EBI-9641086, EBI-739361;
CC       P21333-2; P80217-2: IFI35; NbExp=3; IntAct=EBI-9641086, EBI-12823003;
CC       P21333-2; Q9UKP3-2: ITGB1BP2; NbExp=3; IntAct=EBI-9641086, EBI-25856470;
CC       P21333-2; Q8WZ19: KCTD13; NbExp=3; IntAct=EBI-9641086, EBI-742916;
CC       P21333-2; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-9641086, EBI-743960;
CC       P21333-2; Q53G59: KLHL12; NbExp=6; IntAct=EBI-9641086, EBI-740929;
CC       P21333-2; Q8TCE9: LGALS14; NbExp=6; IntAct=EBI-9641086, EBI-10274069;
CC       P21333-2; Q14693: LPIN1; NbExp=3; IntAct=EBI-9641086, EBI-5278370;
CC       P21333-2; Q8TD91-2: MAGEC3; NbExp=3; IntAct=EBI-9641086, EBI-10694180;
CC       P21333-2; P02795: MT2A; NbExp=3; IntAct=EBI-9641086, EBI-996616;
CC       P21333-2; Q9NP98: MYOZ1; NbExp=6; IntAct=EBI-9641086, EBI-744402;
CC       P21333-2; Q9NQS3: NECTIN3; NbExp=3; IntAct=EBI-9641086, EBI-2826725;
CC       P21333-2; Q9BRX2: PELO; NbExp=6; IntAct=EBI-9641086, EBI-1043580;
CC       P21333-2; Q8TCD6: PHOSPHO2; NbExp=3; IntAct=EBI-9641086, EBI-2861380;
CC       P21333-2; Q9H8W4: PLEKHF2; NbExp=5; IntAct=EBI-9641086, EBI-742388;
CC       P21333-2; O43741: PRKAB2; NbExp=3; IntAct=EBI-9641086, EBI-1053424;
CC       P21333-2; Q09028: RBBP4; NbExp=3; IntAct=EBI-9641086, EBI-620823;
CC       P21333-2; P57052: RBM11; NbExp=3; IntAct=EBI-9641086, EBI-741332;
CC       P21333-2; Q04864: REL; NbExp=3; IntAct=EBI-9641086, EBI-307352;
CC       P21333-2; Q6ZTI6: RFLNA; NbExp=3; IntAct=EBI-9641086, EBI-10200920;
CC       P21333-2; Q6ZTI6-2: RFLNA; NbExp=3; IntAct=EBI-9641086, EBI-12362431;
CC       P21333-2; Q8N488: RYBP; NbExp=3; IntAct=EBI-9641086, EBI-752324;
CC       P21333-2; O15127: SCAMP2; NbExp=3; IntAct=EBI-9641086, EBI-712703;
CC       P21333-2; P08195-4: SLC3A2; NbExp=3; IntAct=EBI-9641086, EBI-12832276;
CC       P21333-2; Q96GM5: SMARCD1; NbExp=3; IntAct=EBI-9641086, EBI-358489;
CC       P21333-2; Q13573: SNW1; NbExp=3; IntAct=EBI-9641086, EBI-632715;
CC       P21333-2; Q9BXN6: SPANXD; NbExp=3; IntAct=EBI-9641086, EBI-10301202;
CC       P21333-2; P15884: TCF4; NbExp=3; IntAct=EBI-9641086, EBI-533224;
CC       P21333-2; P04637: TP53; NbExp=3; IntAct=EBI-9641086, EBI-366083;
CC       P21333-2; Q9NX94: WBP1L; NbExp=3; IntAct=EBI-9641086, EBI-10316321;
CC       P21333-2; Q9BRX9: WDR83; NbExp=3; IntAct=EBI-9641086, EBI-7705033;
CC       P21333-2; O95789-4: ZMYM6; NbExp=3; IntAct=EBI-9641086, EBI-12949277;
CC       P21333-2; Q96E88; NbExp=3; IntAct=EBI-9641086, EBI-10976904;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cell cortex
CC       {ECO:0000269|PubMed:16291724}. Cytoplasm, cytoskeleton
CC       {ECO:0000250|UniProtKB:Q8BTM8}. Perikaryon
CC       {ECO:0000250|UniProtKB:Q8BTM8}. Cell projection, growth cone
CC       {ECO:0000250|UniProtKB:Q8BTM8}. Note=Colocalizes with CPMR1 in the
CC       central region of DRG neuron growth cone (By similarity). Following
CC       SEMA3A stimulation of DRG neurons, colocalizes with F-actin (By
CC       similarity). {ECO:0000250|UniProtKB:Q8BTM8}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P21333-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P21333-2; Sequence=VSP_035454;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- DOMAIN: Comprised of a NH2-terminal actin-binding domain, 24
CC       immunoglobulin-like internally homologous repeats and two hinge
CC       regions. Repeat 24 and the second hinge domain are important for dimer
CC       formation. Filamin repeat 20 interacts with filamin repeat 21 masking
CC       the ligand binding site on filamin repeat 21, resulting in an
CC       autoinhibited conformation (PubMed:17690686). The autoinhibition can be
CC       relieved by ligands like ITGB7 or FBLIM1 (PubMed:21524097). Filamin
CC       repeats 19 and 21 can simultaneously engage ligands (PubMed:21524097).
CC       {ECO:0000269|PubMed:17690686, ECO:0000269|PubMed:21524097}.
CC   -!- PTM: Phosphorylation at Ser-2152 is negatively regulated by the
CC       autoinhibited conformation of filamin repeats 19-21. Ligand binding
CC       induces a conformational switch triggering phosphorylation at Ser-2152
CC       by PKA. {ECO:0000269|PubMed:25666618}.
CC   -!- PTM: Phosphorylation extent changes in response to cell activation.
CC   -!- PTM: Polyubiquitination in the CH1 domain by a SCF-like complex
CC       containing ASB2 leads to proteasomal degradation. Prior dissociation
CC       from actin may be required to expose the target lysines
CC       (PubMed:24052262). Ubiquitinated in endothelial cells by RNF213
CC       downstream of the non-canonical Wnt signaling pathway, leading to its
CC       degradation by the proteasome (PubMed:26766444).
CC       {ECO:0000269|PubMed:24052262, ECO:0000269|PubMed:26766444}.
CC   -!- DISEASE: Periventricular nodular heterotopia 1 (PVNH1) [MIM:300049]: A
CC       developmental disorder characterized by the presence of periventricular
CC       nodules of cerebral gray matter, resulting from a failure of neurons to
CC       migrate normally from the lateral ventricular proliferative zone, where
CC       they are formed, to the cerebral cortex. PVNH1 is an X-linked dominant
CC       form. Heterozygous females have normal intelligence but suffer from
CC       seizures and various manifestations outside the central nervous system,
CC       especially related to the vascular system. Hemizygous affected males
CC       die in the prenatal or perinatal period. {ECO:0000269|PubMed:11532987,
CC       ECO:0000269|PubMed:11914408, ECO:0000269|PubMed:15249610,
CC       ECO:0000269|PubMed:15668422, ECO:0000269|PubMed:15994863,
CC       ECO:0000269|PubMed:16299064}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Otopalatodigital syndrome 1 (OPD1) [MIM:311300]: X-linked
CC       dominant multiple congenital anomalies disease mainly characterized by
CC       a generalized skeletal dysplasia, mild intellectual disability, hearing
CC       loss, cleft palate, and typical facial anomalies. OPD1 belongs to a
CC       group of X-linked skeletal dysplasias known as oto-palato-digital
CC       syndrome spectrum disorders that also include OPD2, Melnick-Needles
CC       syndrome (MNS), and frontometaphyseal dysplasia (FMD). Remodeling of
CC       the cytoskeleton is central to the modulation of cell shape and
CC       migration. FLNA is a widely expressed protein that regulates re-
CC       organization of the actin cytoskeleton by interacting with integrins,
CC       transmembrane receptor complexes and second messengers. Males with OPD1
CC       have cleft palate, malformations of the ossicles causing deafness and
CC       milder bone and limb defects than those associated with OPD2. Obligate
CC       female carriers of mutations causing both OPD1 and OPD2 have variable
CC       (often milder) expression of a similar phenotypic spectrum.
CC       {ECO:0000269|PubMed:12612583, ECO:0000269|PubMed:15940695,
CC       ECO:0000269|PubMed:27193221}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Otopalatodigital syndrome 2 (OPD2) [MIM:304120]: Congenital
CC       bone disorder that is characterized by abnormally modeled, bowed bones,
CC       small or absent first digits and, more variably, cleft palate,
CC       posterior fossa brain anomalies, omphalocele and cardiac defects.
CC       {ECO:0000269|PubMed:12612583, ECO:0000269|PubMed:17431908,
CC       ECO:0000269|PubMed:27193221}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Frontometaphyseal dysplasia 1 (FMD1) [MIM:305620]: An X-linked
CC       disease characterized by generalized skeletal dysplasia, deafness, and
CC       urogenital defects. {ECO:0000269|PubMed:12612583,
CC       ECO:0000269|PubMed:16596676, ECO:0000269|PubMed:27193221}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Melnick-Needles syndrome (MNS) [MIM:309350]: Severe congenital
CC       bone disorder characterized by typical facies (exophthalmos, full
CC       cheeks, micrognathia and malalignment of teeth), flaring of the
CC       metaphyses of long bones, s-like curvature of bones of legs, irregular
CC       constrictions in the ribs, and sclerosis of base of skull.
CC       {ECO:0000269|PubMed:12612583, ECO:0000269|PubMed:27193221}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Intestinal pseudoobstruction, neuronal, chronic idiopathic, X-
CC       linked (IPOX) [MIM:300048]: A disease characterized by a severe
CC       abnormality of gastrointestinal motility due to primary qualitative
CC       defects of enteric ganglia and nerve fibers. Affected individuals
CC       manifest recurrent signs of intestinal obstruction in the absence of
CC       any mechanical lesion. {ECO:0000269|PubMed:17357080}. Note=The disease
CC       is caused by variants affecting the gene represented in this entry.
CC   -!- DISEASE: FG syndrome 2 (FGS2) [MIM:300321]: FG syndrome (FGS) is an X-
CC       linked disorder characterized by intellectual disability, relative
CC       macrocephaly, hypotonia and constipation.
CC       {ECO:0000269|PubMed:17632775}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Terminal osseous dysplasia (TOD) [MIM:300244]: A rare X-linked
CC       dominant male-lethal disease characterized by skeletal dysplasia of the
CC       limbs, pigmentary defects of the skin and recurrent digital fibroma
CC       during infancy. A significant phenotypic variability is observed in
CC       affected females. {ECO:0000269|PubMed:20598277}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Cardiac valvular dysplasia, X-linked (CVDPX) [MIM:314400]: A
CC       rare X-linked heart disease characterized by mitral and/or aortic valve
CC       regurgitation. The histologic features include fragmentation of
CC       collagenous bundles within the valve fibrosa and accumulation of
CC       proteoglycans, which produces excessive valve tissue leading to
CC       billowing of the valve leaflets. {ECO:0000269|PubMed:17190868}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Note=Defects in FLNA may be a cause of macrothrombocytopenia,
CC       a disorder characterized by subnormal levels of blood platelets. Blood
CC       platelets are abnormally enlarged (PubMed:21960593).
CC       {ECO:0000269|PubMed:21960593}.
CC   -!- DISEASE: Congenital short bowel syndrome, X-linked (CSBSX)
CC       [MIM:300048]: A disease characterized by a shortened small intestine,
CC       and malabsorption. The mean length of the small intestine in affected
CC       individuals is approximately 50 cm, compared with a normal length at
CC       birth of 190-280 cm. It is associated with significant mortality and
CC       morbidity. Infants usually present with failure to thrive, recurrent
CC       vomiting, and diarrhea. {ECO:0000269|PubMed:23037936}. Note=The disease
CC       is caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the filamin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC03408.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X53416; CAA37495.1; -; mRNA.
DR   EMBL; L44140; AAA92644.1; -; Genomic_DNA.
DR   EMBL; X70082; CAA49687.1; -; Genomic_DNA.
DR   EMBL; X70085; CAA49690.1; -; Genomic_DNA.
DR   EMBL; GU727643; ADU87644.1; -; mRNA.
DR   EMBL; AK090427; BAC03408.2; ALT_INIT; mRNA.
DR   EMBL; AB593010; BAJ83965.1; -; mRNA.
DR   EMBL; BX664723; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BX936346; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471172; EAW72745.1; -; Genomic_DNA.
DR   EMBL; CH471172; EAW72746.1; -; Genomic_DNA.
DR   CCDS; CCDS44021.1; -. [P21333-2]
DR   CCDS; CCDS48194.1; -. [P21333-1]
DR   PIR; A37098; A37098.
DR   RefSeq; NP_001104026.1; NM_001110556.1. [P21333-1]
DR   RefSeq; NP_001447.2; NM_001456.3. [P21333-2]
DR   PDB; 2AAV; NMR; -; A=1863-1956.
DR   PDB; 2BP3; X-ray; 2.32 A; A/B=1863-1956.
DR   PDB; 2BRQ; X-ray; 2.10 A; A/B=2236-2329.
DR   PDB; 2J3S; X-ray; 2.50 A; A/B=2045-2329.
DR   PDB; 2JF1; X-ray; 2.20 A; A=2236-2329.
DR   PDB; 2K3T; NMR; -; A=2427-2522.
DR   PDB; 2K7P; NMR; -; A=1772-1956.
DR   PDB; 2K7Q; NMR; -; A=1954-2141.
DR   PDB; 2MTP; NMR; -; A=2236-2330.
DR   PDB; 2W0P; X-ray; 1.90 A; A/B=2236-2329.
DR   PDB; 2WFN; X-ray; 3.20 A; A/B=1-278.
DR   PDB; 3CNK; X-ray; 1.65 A; A/B=2559-2647.
DR   PDB; 3HOC; X-ray; 2.30 A; A/B=2-269.
DR   PDB; 3HOP; X-ray; 2.30 A; A/B=2-269.
DR   PDB; 3HOR; X-ray; 2.70 A; A/B=2-269.
DR   PDB; 3ISW; X-ray; 2.80 A; A/B=2236-2329.
DR   PDB; 3RGH; X-ray; 2.44 A; A/B=1158-1252.
DR   PDB; 4M9P; X-ray; 1.72 A; A=478-766.
DR   PDB; 4P3W; X-ray; 2.00 A; A/B/C/D/E/F=2152-2329.
DR   PDB; 5XR1; NMR; -; A=2236-2329.
DR   PDB; 6D8C; EM; 3.54 A; A/B/C/D/E=1-278.
DR   PDB; 6EW1; X-ray; 2.31 A; A=478-766.
DR   PDBsum; 2AAV; -.
DR   PDBsum; 2BP3; -.
DR   PDBsum; 2BRQ; -.
DR   PDBsum; 2J3S; -.
DR   PDBsum; 2JF1; -.
DR   PDBsum; 2K3T; -.
DR   PDBsum; 2K7P; -.
DR   PDBsum; 2K7Q; -.
DR   PDBsum; 2MTP; -.
DR   PDBsum; 2W0P; -.
DR   PDBsum; 2WFN; -.
DR   PDBsum; 3CNK; -.
DR   PDBsum; 3HOC; -.
DR   PDBsum; 3HOP; -.
DR   PDBsum; 3HOR; -.
DR   PDBsum; 3ISW; -.
DR   PDBsum; 3RGH; -.
DR   PDBsum; 4M9P; -.
DR   PDBsum; 4P3W; -.
DR   PDBsum; 5XR1; -.
DR   PDBsum; 6D8C; -.
DR   PDBsum; 6EW1; -.
DR   AlphaFoldDB; P21333; -.
DR   SASBDB; P21333; -.
DR   SMR; P21333; -.
DR   BioGRID; 108605; 517.
DR   ComplexPortal; CPX-117; Glycoprotein Ib-IX-V-Filamin-A complex.
DR   ComplexPortal; CPX-122; Filamin A homodimer.
DR   CORUM; P21333; -.
DR   DIP; DIP-1136N; -.
DR   IntAct; P21333; 320.
DR   MINT; P21333; -.
DR   STRING; 9606.ENSP00000358866; -.
DR   ChEMBL; CHEMBL4804243; -.
DR   DrugBank; DB11638; Artenimol.
DR   MoonDB; P21333; Predicted.
DR   TCDB; 8.A.66.1.4; the dystrophin (dystrophin) family.
DR   CarbonylDB; P21333; -.
DR   GlyCosmos; P21333; 4 sites, 2 glycans.
DR   GlyGen; P21333; 7 sites, 2 O-linked glycans (7 sites).
DR   iPTMnet; P21333; -.
DR   MetOSite; P21333; -.
DR   PhosphoSitePlus; P21333; -.
DR   SwissPalm; P21333; -.
DR   BioMuta; FLNA; -.
DR   DMDM; 116241365; -.
DR   OGP; P21333; -.
DR   CPTAC; CPTAC-508; -.
DR   CPTAC; CPTAC-509; -.
DR   EPD; P21333; -.
DR   jPOST; P21333; -.
DR   MassIVE; P21333; -.
DR   MaxQB; P21333; -.
DR   PaxDb; P21333; -.
DR   PeptideAtlas; P21333; -.
DR   PRIDE; P21333; -.
DR   ProteomicsDB; 53859; -. [P21333-1]
DR   ProteomicsDB; 53860; -. [P21333-2]
DR   ABCD; P21333; 3 sequenced antibodies.
DR   Antibodypedia; 341; 797 antibodies from 39 providers.
DR   DNASU; 2316; -.
DR   Ensembl; ENST00000360319.9; ENSP00000353467.4; ENSG00000196924.19. [P21333-2]
DR   Ensembl; ENST00000369850.10; ENSP00000358866.3; ENSG00000196924.19. [P21333-1]
DR   GeneID; 2316; -.
DR   KEGG; hsa:2316; -.
DR   MANE-Select; ENST00000369850.10; ENSP00000358866.3; NM_001110556.2; NP_001104026.1.
DR   UCSC; uc004fkk.3; human. [P21333-1]
DR   AGR; HGNC:3754; -.
DR   CTD; 2316; -.
DR   DisGeNET; 2316; -.
DR   GeneCards; FLNA; -.
DR   GeneReviews; FLNA; -.
DR   HGNC; HGNC:3754; FLNA.
DR   HPA; ENSG00000196924; Tissue enhanced (endometrium, intestine).
DR   MalaCards; FLNA; -.
DR   MIM; 300017; gene.
DR   MIM; 300048; phenotype.
DR   MIM; 300049; phenotype.
DR   MIM; 300244; phenotype.
DR   MIM; 300321; phenotype.
DR   MIM; 304120; phenotype.
DR   MIM; 305620; phenotype.
DR   MIM; 309350; phenotype.
DR   MIM; 311300; phenotype.
DR   MIM; 314400; phenotype.
DR   neXtProt; NX_P21333; -.
DR   OpenTargets; ENSG00000196924; -.
DR   Orphanet; 2301; Congenital short bowel syndrome.
DR   Orphanet; 555877; FLNA-related X-linked myxomatous valvular dysplasia.
DR   Orphanet; 1826; Frontometaphyseal dysplasia.
DR   Orphanet; 2484; Melnick-Needles syndrome.
DR   Orphanet; 99811; Neuronal intestinal pseudoobstruction.
DR   Orphanet; 323; NON RARE IN EUROPE: FG syndrome phenotypic spectrum.
DR   Orphanet; 90650; Otopalatodigital syndrome type 1.
DR   Orphanet; 90652; Otopalatodigital syndrome type 2.
DR   Orphanet; 98892; Periventricular nodular heterotopia.
DR   Orphanet; 88630; Terminal osseous dysplasia-pigmentary defects syndrome.
DR   Orphanet; 75497; X-linked Ehlers-Danlos syndrome.
DR   Orphanet; 482606; X-linked keloid scarring-reduced joint mobility-increased optic cup-to-disc ratio syndrome.
DR   PharmGKB; PA28172; -.
DR   VEuPathDB; HostDB:ENSG00000196924; -.
DR   eggNOG; KOG0518; Eukaryota.
DR   GeneTree; ENSGT00940000153588; -.
DR   InParanoid; P21333; -.
DR   OMA; KWADEHI; -.
DR   OrthoDB; 298396at2759; -.
DR   PhylomeDB; P21333; -.
DR   TreeFam; TF313685; -.
DR   PathwayCommons; P21333; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-430116; GP1b-IX-V activation signalling.
DR   Reactome; R-HSA-446353; Cell-extracellular matrix interactions.
DR   Reactome; R-HSA-5627123; RHO GTPases activate PAKs.
DR   Reactome; R-HSA-8983711; OAS antiviral response.
DR   SignaLink; P21333; -.
DR   SIGNOR; P21333; -.
DR   BioGRID-ORCS; 2316; 14 hits in 785 CRISPR screens.
DR   ChiTaRS; FLNA; human.
DR   EvolutionaryTrace; P21333; -.
DR   GeneWiki; FLNA; -.
DR   GenomeRNAi; 2316; -.
DR   Pharos; P21333; Tbio.
DR   PRO; PR:P21333; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P21333; protein.
DR   Bgee; ENSG00000196924; Expressed in right coronary artery and 198 other tissues.
DR   ExpressionAtlas; P21333; baseline and differential.
DR   Genevisible; P21333; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:WormBase.
DR   GO; GO:0032432; C:actin filament bundle; IEA:Ensembl.
DR   GO; GO:0044295; C:axonal growth cone; IEA:Ensembl.
DR   GO; GO:0005903; C:brush border; IEA:Ensembl.
DR   GO; GO:0005938; C:cell cortex; IEA:UniProtKB-SubCell.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:1990779; C:glycoprotein Ib-IX-V complex; NAS:ComplexPortal.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0031523; C:Myb complex; IDA:MGI.
DR   GO; GO:0005730; C:nucleolus; IMP:CACAO.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043204; C:perikaryon; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005802; C:trans-Golgi network; IEA:Ensembl.
DR   GO; GO:0030018; C:Z disc; ISS:BHF-UCL.
DR   GO; GO:0051015; F:actin filament binding; IDA:BHF-UCL.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0034988; F:Fc-gamma receptor I complex binding; IDA:BHF-UCL.
DR   GO; GO:0001664; F:G protein-coupled receptor binding; IPI:UniProtKB.
DR   GO; GO:0051020; F:GTPase binding; IPI:UniProtKB.
DR   GO; GO:0019900; F:kinase binding; IPI:UniProtKB.
DR   GO; GO:0015459; F:potassium channel regulator activity; IDA:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0005080; F:protein kinase C binding; IEA:Ensembl.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0031267; F:small GTPase binding; IDA:BHF-UCL.
DR   GO; GO:0044325; F:transmembrane transporter binding; IPI:BHF-UCL.
DR   GO; GO:0051764; P:actin crosslink formation; IDA:BHF-UCL.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IDA:BHF-UCL.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; IDA:ComplexPortal.
DR   GO; GO:0007195; P:adenylate cyclase-inhibiting dopamine receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0001525; P:angiogenesis; IEA:Ensembl.
DR   GO; GO:0007597; P:blood coagulation, intrinsic pathway; NAS:ComplexPortal.
DR   GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0045216; P:cell-cell junction organization; IEA:Ensembl.
DR   GO; GO:0060271; P:cilium assembly; IMP:UniProtKB.
DR   GO; GO:0051220; P:cytoplasmic sequestering of protein; IMP:BHF-UCL.
DR   GO; GO:0045022; P:early endosome to late endosome transport; IEA:Ensembl.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IEA:Ensembl.
DR   GO; GO:0045184; P:establishment of protein localization; IDA:BHF-UCL.
DR   GO; GO:0003007; P:heart morphogenesis; IEA:Ensembl.
DR   GO; GO:0035855; P:megakaryocyte development; NAS:ComplexPortal.
DR   GO; GO:0090307; P:mitotic spindle assembly; IDA:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:CACAO.
DR   GO; GO:0043433; P:negative regulation of DNA-binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IMP:BHF-UCL.
DR   GO; GO:0016479; P:negative regulation of transcription by RNA polymerase I; IDA:CACAO.
DR   GO; GO:0070527; P:platelet aggregation; HMP:UniProtKB.
DR   GO; GO:0048680; P:positive regulation of axon regeneration; IEA:Ensembl.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; HMP:UniProtKB.
DR   GO; GO:2001046; P:positive regulation of integrin-mediated signaling pathway; IMP:CACAO.
DR   GO; GO:0010572; P:positive regulation of platelet activation; NAS:ComplexPortal.
DR   GO; GO:1901381; P:positive regulation of potassium ion transmembrane transport; IDA:BHF-UCL.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IMP:UniProtKB.
DR   GO; GO:1900026; P:positive regulation of substrate adhesion-dependent cell spreading; IMP:CACAO.
DR   GO; GO:0034394; P:protein localization to cell surface; IDA:BHF-UCL.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0050821; P:protein stabilization; IMP:BHF-UCL.
DR   GO; GO:0043113; P:receptor clustering; IDA:BHF-UCL.
DR   GO; GO:0032231; P:regulation of actin filament bundle assembly; IEA:Ensembl.
DR   GO; GO:0030334; P:regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:1905000; P:regulation of membrane repolarization during atrial cardiac muscle cell action potential; IC:BHF-UCL.
DR   GO; GO:1905031; P:regulation of membrane repolarization during cardiac muscle cell action potential; ISS:BHF-UCL.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; NAS:ComplexPortal.
DR   GO; GO:0071526; P:semaphorin-plexin signaling pathway; IGI:WormBase.
DR   GO; GO:0050808; P:synapse organization; IEA:Ensembl.
DR   GO; GO:0090042; P:tubulin deacetylation; IMP:CACAO.
DR   GO; GO:0044319; P:wound healing, spreading of cells; IDA:UniProtKB.
DR   CDD; cd21308; CH_FLNA_rpt1; 1.
DR   CDD; cd21312; CH_FLNA_rpt2; 1.
DR   DisProt; DP01950; -.
DR   Gene3D; 1.10.418.10; Calponin-like domain; 2.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 24.
DR   InterPro; IPR001589; Actinin_actin-bd_CS.
DR   InterPro; IPR001715; CH_dom.
DR   InterPro; IPR036872; CH_dom_sf.
DR   InterPro; IPR044801; Filamin.
DR   InterPro; IPR017868; Filamin/ABP280_repeat-like.
DR   InterPro; IPR001298; Filamin/ABP280_rpt.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   PANTHER; PTHR38537:SF8; FILAMIN-A; 1.
DR   PANTHER; PTHR38537; JITTERBUG, ISOFORM N; 1.
DR   Pfam; PF00307; CH; 2.
DR   Pfam; PF00630; Filamin; 23.
DR   SMART; SM00033; CH; 2.
DR   SMART; SM00557; IG_FLMN; 24.
DR   SUPFAM; SSF47576; Calponin-homology domain, CH-domain; 1.
DR   SUPFAM; SSF81296; E set domains; 24.
DR   PROSITE; PS00019; ACTININ_1; 1.
DR   PROSITE; PS00020; ACTININ_2; 1.
DR   PROSITE; PS50021; CH; 2.
DR   PROSITE; PS50194; FILAMIN_REPEAT; 24.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Actin-binding; Alternative splicing;
KW   Cell projection; Cilium biogenesis/degradation; Cytoplasm; Cytoskeleton;
KW   Deafness; Direct protein sequencing; Disease variant; Isopeptide bond;
KW   Phosphoprotein; Reference proteome; Repeat; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.9, ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:25944712"
FT   CHAIN           2..2647
FT                   /note="Filamin-A"
FT                   /id="PRO_0000087296"
FT   DOMAIN          43..149
FT                   /note="Calponin-homology (CH) 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00044"
FT   DOMAIN          166..269
FT                   /note="Calponin-homology (CH) 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00044"
FT   REPEAT          276..374
FT                   /note="Filamin 1"
FT   REPEAT          376..474
FT                   /note="Filamin 2"
FT   REPEAT          475..570
FT                   /note="Filamin 3"
FT   REPEAT          571..663
FT                   /note="Filamin 4"
FT   REPEAT          667..763
FT                   /note="Filamin 5"
FT   REPEAT          764..866
FT                   /note="Filamin 6"
FT   REPEAT          867..965
FT                   /note="Filamin 7"
FT   REPEAT          966..1061
FT                   /note="Filamin 8"
FT   REPEAT          1062..1154
FT                   /note="Filamin 9"
FT   REPEAT          1155..1249
FT                   /note="Filamin 10"
FT   REPEAT          1250..1349
FT                   /note="Filamin 11"
FT   REPEAT          1350..1442
FT                   /note="Filamin 12"
FT   REPEAT          1443..1539
FT                   /note="Filamin 13"
FT   REPEAT          1540..1636
FT                   /note="Filamin 14"
FT   REPEAT          1649..1740
FT                   /note="Filamin 15"
FT   REPEAT          1779..1860
FT                   /note="Filamin 16"
FT   REPEAT          1861..1950
FT                   /note="Filamin 17"
FT   REPEAT          1951..2039
FT                   /note="Filamin 18"
FT   REPEAT          2042..2131
FT                   /note="Filamin 19"
FT   REPEAT          2132..2230
FT                   /note="Filamin 20"
FT   REPEAT          2233..2325
FT                   /note="Filamin 21"
FT   REPEAT          2327..2420
FT                   /note="Filamin 22"
FT   REPEAT          2424..2516
FT                   /note="Filamin 23"
FT   REPEAT          2552..2646
FT                   /note="Filamin 24"
FT   REGION          1..39
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2..274
FT                   /note="Actin-binding"
FT   REGION          271..294
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1361..1382
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1490..1607
FT                   /note="Interaction with furin"
FT                   /evidence="ECO:0000250"
FT   REGION          1741..1778
FT                   /note="Hinge 1"
FT   REGION          2517..2647
FT                   /note="Self-association site, tail"
FT   REGION          2517..2551
FT                   /note="Hinge 2"
FT   COMPBIAS        1363..1378
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            1761..1762
FT                   /note="Cleavage; by calpain"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000269|Ref.9, ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:25944712"
FT   MOD_RES         11
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         376
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         508
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         700
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         781
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         837
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         865
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         906
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         968
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         1055
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1071
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         1071
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         1081
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1084
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:17924679, ECO:0007744|PubMed:18088087,
FT                   ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1089
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17081983"
FT   MOD_RES         1301
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1338
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1372
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         1459
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:18088087,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19367720,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1533
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1538
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         1630
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1734
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1835
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1967
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         2053
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         2128
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2152
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:25666618,
FT                   ECO:0000269|PubMed:26460884, ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18088087, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         2158
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18088087,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         2163
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         2180
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         2284
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         2327
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         2329
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         2336
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:25666618,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         2338
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         2370
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         2414
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         2510
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         2523
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         2526
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         2569
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         2569
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         2575
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         2599
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BTM8"
FT   MOD_RES         2607
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         2621
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   CROSSLNK        42
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:24052262"
FT   CROSSLNK        43
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:24052262"
FT   CROSSLNK        135
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:24052262"
FT   CROSSLNK        299
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        299
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1649..1656
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_035454"
FT   VARIANT         39
FT                   /note="A -> G (in PVNH1; dbSNP:rs137853313)"
FT                   /evidence="ECO:0000269|PubMed:15668422"
FT                   /id="VAR_022734"
FT   VARIANT         82
FT                   /note="E -> V (in PVNH1; dbSNP:rs28935169)"
FT                   /evidence="ECO:0000269|PubMed:11914408"
FT                   /id="VAR_015699"
FT   VARIANT         102
FT                   /note="M -> V (in PVNH1)"
FT                   /evidence="ECO:0000269|PubMed:15249610"
FT                   /id="VAR_031305"
FT   VARIANT         128
FT                   /note="A -> V (in PVNH1; dbSNP:rs137853315)"
FT                   /evidence="ECO:0000269|PubMed:15994863"
FT                   /id="VAR_031306"
FT   VARIANT         149
FT                   /note="S -> F (in PVNH1)"
FT                   /evidence="ECO:0000269|PubMed:15249610"
FT                   /id="VAR_031307"
FT   VARIANT         170
FT                   /note="Q -> P (in OPD2; dbSNP:rs863223628)"
FT                   /evidence="ECO:0000269|PubMed:12612583"
FT                   /id="VAR_015713"
FT   VARIANT         172
FT                   /note="L -> F (in OPD1)"
FT                   /evidence="ECO:0000269|PubMed:12612583"
FT                   /id="VAR_015714"
FT   VARIANT         187
FT                   /note="N -> S (in OPD2; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:27193221"
FT                   /id="VAR_076500"
FT   VARIANT         196
FT                   /note="R -> G (in OPD2)"
FT                   /evidence="ECO:0000269|PubMed:12612583,
FT                   ECO:0000269|PubMed:27193221"
FT                   /id="VAR_015715"
FT   VARIANT         196
FT                   /note="R -> W (in OPD1; dbSNP:rs137853317)"
FT                   /evidence="ECO:0000269|PubMed:12612583"
FT                   /id="VAR_015716"
FT   VARIANT         200
FT                   /note="A -> S (in OPD2)"
FT                   /evidence="ECO:0000269|PubMed:12612583"
FT                   /id="VAR_015717"
FT   VARIANT         203
FT                   /note="D -> Y (in OPD1; dbSNP:rs137853314)"
FT                   /evidence="ECO:0000269|PubMed:15940695"
FT                   /id="VAR_031308"
FT   VARIANT         207
FT                   /note="P -> L (in OPD1; dbSNP:rs28935469)"
FT                   /evidence="ECO:0000269|PubMed:12612583,
FT                   ECO:0000269|PubMed:27193221"
FT                   /id="VAR_015700"
FT   VARIANT         210
FT                   /note="C -> F (in OPD2; dbSNP:rs137853318)"
FT                   /evidence="ECO:0000269|PubMed:17431908"
FT                   /id="VAR_058720"
FT   VARIANT         254
FT                   /note="E -> K (in OPD2; dbSNP:rs28935470)"
FT                   /evidence="ECO:0000269|PubMed:12612583"
FT                   /id="VAR_015701"
FT   VARIANT         267
FT                   /note="A -> T (in OPD1; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:27193221"
FT                   /id="VAR_076501"
FT   VARIANT         273
FT                   /note="A -> P (in OPD2)"
FT                   /evidence="ECO:0000269|PubMed:12612583"
FT                   /id="VAR_015718"
FT   VARIANT         288
FT                   /note="G -> R (in CVDPX; dbSNP:rs267606816)"
FT                   /evidence="ECO:0000269|PubMed:17190868"
FT                   /id="VAR_064156"
FT   VARIANT         320
FT                   /note="V -> A (in dbSNP:rs1064816)"
FT                   /id="VAR_012831"
FT   VARIANT         370
FT                   /note="F -> L (in dbSNP:rs1064817)"
FT                   /id="VAR_012832"
FT   VARIANT         429
FT                   /note="T -> M (in dbSNP:rs36051194)"
FT                   /evidence="ECO:0000269|PubMed:12612583"
FT                   /id="VAR_069803"
FT   VARIANT         528
FT                   /note="V -> M (in dbSNP:rs143873938)"
FT                   /evidence="ECO:0000269|PubMed:12410386,
FT                   ECO:0000269|PubMed:20844545"
FT                   /id="VAR_031309"
FT   VARIANT         552
FT                   /note="V -> A (in dbSNP:rs730319)"
FT                   /id="VAR_012833"
FT   VARIANT         555
FT                   /note="T -> K (in OPD2; dbSNP:rs782611953)"
FT                   /evidence="ECO:0000269|PubMed:12612583"
FT                   /id="VAR_015719"
FT   VARIANT         606
FT                   /note="V -> L (found in a child with developmental
FT                   disabilities; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:30500825"
FT                   /id="VAR_085766"
FT   VARIANT         637
FT                   /note="P -> Q (in CVDPX; dbSNP:rs267606815)"
FT                   /evidence="ECO:0000269|PubMed:17190868"
FT                   /id="VAR_064157"
FT   VARIANT         656
FT                   /note="L -> F (in PVNH1; dbSNP:rs137853311)"
FT                   /evidence="ECO:0000269|PubMed:11532987"
FT                   /id="VAR_012834"
FT   VARIANT         711
FT                   /note="V -> D (in CVDPX; dbSNP:rs267606817)"
FT                   /evidence="ECO:0000269|PubMed:17190868"
FT                   /id="VAR_064158"
FT   VARIANT         804
FT                   /note="V -> D (in OPD1; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:27193221"
FT                   /id="VAR_076502"
FT   VARIANT         1012
FT                   /note="S -> L (in dbSNP:rs17091204)"
FT                   /id="VAR_031310"
FT   VARIANT         1142
FT                   /note="D -> V (in FMD1; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:27193221"
FT                   /id="VAR_076503"
FT   VARIANT         1159
FT                   /note="D -> A (in FMD1; does not inhibit interaction with
FT                   MIS18BP1; dbSNP:rs28935471)"
FT                   /evidence="ECO:0000269|PubMed:12612583,
FT                   ECO:0000269|PubMed:21228480"
FT                   /id="VAR_015702"
FT   VARIANT         1163
FT                   /note="V -> L (in MNS; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:27193221"
FT                   /id="VAR_076504"
FT   VARIANT         1184
FT                   /note="D -> E (in MNS; dbSNP:rs80338837)"
FT                   /evidence="ECO:0000269|PubMed:12612583"
FT                   /id="VAR_015720"
FT   VARIANT         1186
FT                   /note="S -> L (in FMD1; dbSNP:rs137853312)"
FT                   /evidence="ECO:0000269|PubMed:12612583,
FT                   ECO:0000269|PubMed:16596676, ECO:0000269|PubMed:27193221"
FT                   /id="VAR_015721"
FT   VARIANT         1188
FT                   /note="A -> T (in MNS; does not inhibit interaction with
FT                   MIS18BP1; dbSNP:rs28935472)"
FT                   /evidence="ECO:0000269|PubMed:12612583,
FT                   ECO:0000269|PubMed:21228480, ECO:0000269|PubMed:27193221"
FT                   /id="VAR_015703"
FT   VARIANT         1199
FT                   /note="S -> L (in MNS; does not inhibit interaction with
FT                   MIS18BP1; dbSNP:rs28935473)"
FT                   /evidence="ECO:0000269|PubMed:12612583,
FT                   ECO:0000269|PubMed:21228480"
FT                   /id="VAR_015704"
FT   VARIANT         1291
FT                   /note="P -> L (in FGS2; dbSNP:rs137853319)"
FT                   /evidence="ECO:0000269|PubMed:17632775"
FT                   /id="VAR_058721"
FT   VARIANT         1419
FT                   /note="A -> G (in dbSNP:rs35504556)"
FT                   /id="VAR_032083"
FT   VARIANT         1620
FT                   /note="Missing (in FMD1)"
FT                   /evidence="ECO:0000269|PubMed:12612583"
FT                   /id="VAR_015722"
FT   VARIANT         1635..1637
FT                   /note="Missing (in otopalatodigital spectrum disorder)"
FT                   /evidence="ECO:0000269|PubMed:15654694"
FT                   /id="VAR_031311"
FT   VARIANT         1645
FT                   /note="C -> F (in OPD2)"
FT                   /evidence="ECO:0000269|PubMed:12612583"
FT                   /id="VAR_015723"
FT   VARIANT         1724..1739
FT                   /note="Missing (in TOD)"
FT                   /evidence="ECO:0000269|PubMed:20598277"
FT                   /id="VAR_064159"
FT   VARIANT         1728
FT                   /note="G -> C (in FMD1; dbSNP:rs137853316)"
FT                   /evidence="ECO:0000269|PubMed:16596676"
FT                   /id="VAR_031312"
FT   VARIANT         1764
FT                   /note="A -> T (in dbSNP:rs57108893)"
FT                   /evidence="ECO:0000269|PubMed:11532987,
FT                   ECO:0000269|PubMed:12612583"
FT                   /id="VAR_012835"
FT   VARIANT         1803
FT                   /note="E -> K (probable disease-associated variant found in
FT                   a patient with macrothrombocytopenia; dbSNP:rs368750879)"
FT                   /evidence="ECO:0000269|PubMed:21960593"
FT                   /id="VAR_067251"
FT   VARIANT         1840
FT                   /note="H -> R (in FMD1; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:27193221"
FT                   /id="VAR_076505"
FT   VARIANT         2391
FT                   /note="R -> H (in OPD1; unknown pathological significance;
FT                   dbSNP:rs727503930)"
FT                   /evidence="ECO:0000269|PubMed:27193221"
FT                   /id="VAR_076506"
FT   MUTAGEN         42
FT                   /note="K->R: Abrogates ASB2alpha-mediated degradation
FT                   without altering ASB2alpha binding; when associated with
FT                   R-43 and R-135."
FT                   /evidence="ECO:0000269|PubMed:24052262"
FT   MUTAGEN         43
FT                   /note="K->R: Abrogates ASB2alpha-mediated degradation
FT                   without altering ASB2alpha binding; when associated with
FT                   R-42 and R-135."
FT                   /evidence="ECO:0000269|PubMed:24052262"
FT   MUTAGEN         135
FT                   /note="K->R: Abrogates ASB2alpha-mediated degradation
FT                   without altering ASB2alpha binding; when associated with
FT                   R-42 and R-43."
FT                   /evidence="ECO:0000269|PubMed:24052262"
FT   CONFLICT        44
FT                   /note="I -> T (in Ref. 10; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1772
FT                   /note="A -> G (in Ref. 11; CAA49687)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2341
FT                   /note="Q -> R (in Ref. 5; BAC03408)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2634
FT                   /note="D -> H (in Ref. 2; CAA37495)"
FT                   /evidence="ECO:0000305"
FT   HELIX           40..43
FT                   /evidence="ECO:0007829|PDB:3HOC"
FT   HELIX           44..57
FT                   /evidence="ECO:0007829|PDB:3HOC"
FT   HELIX           58..60
FT                   /evidence="ECO:0007829|PDB:3HOC"
FT   TURN            67..73
FT                   /evidence="ECO:0007829|PDB:3HOC"
FT   HELIX           75..85
FT                   /evidence="ECO:0007829|PDB:3HOC"
FT   HELIX           100..116
FT                   /evidence="ECO:0007829|PDB:3HOC"
FT   HELIX           126..130
FT                   /evidence="ECO:0007829|PDB:3HOC"
FT   HELIX           134..149
FT                   /evidence="ECO:0007829|PDB:3HOC"
FT   STRAND          157..159
FT                   /evidence="ECO:0007829|PDB:3HOP"
FT   HELIX           168..179
FT                   /evidence="ECO:0007829|PDB:3HOC"
FT   STRAND          181..183
FT                   /evidence="ECO:0007829|PDB:3HOR"
FT   HELIX           190..192
FT                   /evidence="ECO:0007829|PDB:3HOC"
FT   STRAND          193..195
FT                   /evidence="ECO:0007829|PDB:3HOR"
FT   HELIX           196..205
FT                   /evidence="ECO:0007829|PDB:3HOC"
FT   HELIX           213..215
FT                   /evidence="ECO:0007829|PDB:3HOC"
FT   HELIX           221..236
FT                   /evidence="ECO:0007829|PDB:3HOC"
FT   HELIX           244..247
FT                   /evidence="ECO:0007829|PDB:3HOC"
FT   HELIX           254..261
FT                   /evidence="ECO:0007829|PDB:3HOC"
FT   HELIX           263..266
FT                   /evidence="ECO:0007829|PDB:3HOP"
FT   HELIX           480..482
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          484..487
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   HELIX           488..490
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          501..506
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          515..521
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          529..534
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          537..542
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          548..556
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          565..571
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          579..583
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   HELIX           584..586
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          588..590
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          595..604
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          609..617
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          620..625
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          627..636
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          639..649
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          658..664
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   HELIX           672..674
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          676..679
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   HELIX           680..682
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          683..685
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          693..698
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          707..712
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          714..716
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          721..725
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          727..735
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          739..749
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   STRAND          758..762
FT                   /evidence="ECO:0007829|PDB:4M9P"
FT   HELIX           1160..1162
FT                   /evidence="ECO:0007829|PDB:3RGH"
FT   STRAND          1164..1167
FT                   /evidence="ECO:0007829|PDB:3RGH"
FT   HELIX           1168..1170
FT                   /evidence="ECO:0007829|PDB:3RGH"
FT   STRAND          1172..1174
FT                   /evidence="ECO:0007829|PDB:3RGH"
FT   STRAND          1179..1184
FT                   /evidence="ECO:0007829|PDB:3RGH"
FT   STRAND          1193..1198
FT                   /evidence="ECO:0007829|PDB:3RGH"
FT   STRAND          1206..1211
FT                   /evidence="ECO:0007829|PDB:3RGH"
FT   STRAND          1213..1222
FT                   /evidence="ECO:0007829|PDB:3RGH"
FT   STRAND          1225..1235
FT                   /evidence="ECO:0007829|PDB:3RGH"
FT   STRAND          1244..1250
FT                   /evidence="ECO:0007829|PDB:3RGH"
FT   TURN            1785..1787
FT                   /evidence="ECO:0007829|PDB:2K7P"
FT   STRAND          1791..1796
FT                   /evidence="ECO:0007829|PDB:2K7P"
FT   STRAND          1804..1809
FT                   /evidence="ECO:0007829|PDB:2K7P"
FT   STRAND          1819..1822
FT                   /evidence="ECO:0007829|PDB:2K7P"
FT   STRAND          1824..1832
FT                   /evidence="ECO:0007829|PDB:2K7P"
FT   STRAND          1838..1846
FT                   /evidence="ECO:0007829|PDB:2K7P"
FT   STRAND          1855..1860
FT                   /evidence="ECO:0007829|PDB:2K7P"
FT   STRAND          1865..1867
FT                   /evidence="ECO:0007829|PDB:2K7P"
FT   STRAND          1869..1872
FT                   /evidence="ECO:0007829|PDB:2BP3"
FT   HELIX           1873..1875
FT                   /evidence="ECO:0007829|PDB:2BP3"
FT   STRAND          1877..1879
FT                   /evidence="ECO:0007829|PDB:2BP3"
FT   STRAND          1884..1889
FT                   /evidence="ECO:0007829|PDB:2BP3"
FT   TURN            1891..1893
FT                   /evidence="ECO:0007829|PDB:2AAV"
FT   STRAND          1895..1906
FT                   /evidence="ECO:0007829|PDB:2BP3"
FT   STRAND          1909..1914
FT                   /evidence="ECO:0007829|PDB:2BP3"
FT   STRAND          1916..1925
FT                   /evidence="ECO:0007829|PDB:2BP3"
FT   STRAND          1930..1938
FT                   /evidence="ECO:0007829|PDB:2BP3"
FT   STRAND          1947..1953
FT                   /evidence="ECO:0007829|PDB:2BP3"
FT   STRAND          1959..1967
FT                   /evidence="ECO:0007829|PDB:2K7Q"
FT   STRAND          1980..1988
FT                   /evidence="ECO:0007829|PDB:2K7Q"
FT   STRAND          1998..2001
FT                   /evidence="ECO:0007829|PDB:2K7Q"
FT   STRAND          2007..2010
FT                   /evidence="ECO:0007829|PDB:2K7Q"
FT   STRAND          2014..2025
FT                   /evidence="ECO:0007829|PDB:2K7Q"
FT   STRAND          2034..2039
FT                   /evidence="ECO:0007829|PDB:2K7Q"
FT   HELIX           2041..2043
FT                   /evidence="ECO:0007829|PDB:2K7Q"
FT   HELIX           2047..2049
FT                   /evidence="ECO:0007829|PDB:2J3S"
FT   STRAND          2051..2054
FT                   /evidence="ECO:0007829|PDB:2J3S"
FT   HELIX           2055..2057
FT                   /evidence="ECO:0007829|PDB:2J3S"
FT   STRAND          2059..2061
FT                   /evidence="ECO:0007829|PDB:2J3S"
FT   STRAND          2066..2071
FT                   /evidence="ECO:0007829|PDB:2J3S"
FT   STRAND          2075..2077
FT                   /evidence="ECO:0007829|PDB:2J3S"
FT   STRAND          2080..2088
FT                   /evidence="ECO:0007829|PDB:2J3S"
FT   STRAND          2091..2096
FT                   /evidence="ECO:0007829|PDB:2J3S"
FT   STRAND          2100..2107
FT                   /evidence="ECO:0007829|PDB:2J3S"
FT   STRAND          2112..2120
FT                   /evidence="ECO:0007829|PDB:2J3S"
FT   STRAND          2129..2136
FT                   /evidence="ECO:0007829|PDB:2J3S"
FT   STRAND          2139..2148
FT                   /evidence="ECO:0007829|PDB:2J3S"
FT   STRAND          2161..2165
FT                   /evidence="ECO:0007829|PDB:4P3W"
FT   HELIX           2171..2173
FT                   /evidence="ECO:0007829|PDB:4P3W"
FT   STRAND          2174..2179
FT                   /evidence="ECO:0007829|PDB:4P3W"
FT   STRAND          2185..2187
FT                   /evidence="ECO:0007829|PDB:4P3W"
FT   STRAND          2189..2192
FT                   /evidence="ECO:0007829|PDB:4P3W"
FT   STRAND          2194..2201
FT                   /evidence="ECO:0007829|PDB:4P3W"
FT   STRAND          2208..2216
FT                   /evidence="ECO:0007829|PDB:4P3W"
FT   STRAND          2225..2229
FT                   /evidence="ECO:0007829|PDB:4P3W"
FT   STRAND          2234..2236
FT                   /evidence="ECO:0007829|PDB:4P3W"
FT   HELIX           2238..2240
FT                   /evidence="ECO:0007829|PDB:2W0P"
FT   STRAND          2242..2245
FT                   /evidence="ECO:0007829|PDB:2W0P"
FT   HELIX           2246..2248
FT                   /evidence="ECO:0007829|PDB:2W0P"
FT   STRAND          2251..2253
FT                   /evidence="ECO:0007829|PDB:5XR1"
FT   STRAND          2257..2262
FT                   /evidence="ECO:0007829|PDB:2W0P"
FT   HELIX           2264..2266
FT                   /evidence="ECO:0007829|PDB:2W0P"
FT   STRAND          2271..2279
FT                   /evidence="ECO:0007829|PDB:2W0P"
FT   STRAND          2282..2287
FT                   /evidence="ECO:0007829|PDB:2W0P"
FT   STRAND          2293..2298
FT                   /evidence="ECO:0007829|PDB:2W0P"
FT   STRAND          2303..2311
FT                   /evidence="ECO:0007829|PDB:2W0P"
FT   TURN            2316..2318
FT                   /evidence="ECO:0007829|PDB:5XR1"
FT   STRAND          2320..2326
FT                   /evidence="ECO:0007829|PDB:2W0P"
FT   TURN            2429..2431
FT                   /evidence="ECO:0007829|PDB:2K3T"
FT   STRAND          2433..2436
FT                   /evidence="ECO:0007829|PDB:2K3T"
FT   HELIX           2437..2439
FT                   /evidence="ECO:0007829|PDB:2K3T"
FT   STRAND          2441..2443
FT                   /evidence="ECO:0007829|PDB:2K3T"
FT   STRAND          2448..2453
FT                   /evidence="ECO:0007829|PDB:2K3T"
FT   TURN            2455..2457
FT                   /evidence="ECO:0007829|PDB:2K3T"
FT   STRAND          2462..2470
FT                   /evidence="ECO:0007829|PDB:2K3T"
FT   STRAND          2472..2479
FT                   /evidence="ECO:0007829|PDB:2K3T"
FT   STRAND          2482..2489
FT                   /evidence="ECO:0007829|PDB:2K3T"
FT   STRAND          2491..2506
FT                   /evidence="ECO:0007829|PDB:2K3T"
FT   STRAND          2511..2518
FT                   /evidence="ECO:0007829|PDB:2K3T"
FT   STRAND          2561..2564
FT                   /evidence="ECO:0007829|PDB:3CNK"
FT   HELIX           2565..2567
FT                   /evidence="ECO:0007829|PDB:3CNK"
FT   STRAND          2576..2581
FT                   /evidence="ECO:0007829|PDB:3CNK"
FT   STRAND          2590..2595
FT                   /evidence="ECO:0007829|PDB:3CNK"
FT   STRAND          2597..2599
FT                   /evidence="ECO:0007829|PDB:3CNK"
FT   STRAND          2602..2610
FT                   /evidence="ECO:0007829|PDB:3CNK"
FT   STRAND          2613..2619
FT                   /evidence="ECO:0007829|PDB:3CNK"
FT   STRAND          2624..2632
FT                   /evidence="ECO:0007829|PDB:3CNK"
FT   STRAND          2641..2646
FT                   /evidence="ECO:0007829|PDB:3CNK"
SQ   SEQUENCE   2647 AA;  280739 MW;  6C1A07041DF50142 CRC64;
     MSSSHSRAGQ SAAGAAPGGG VDTRDAEMPA TEKDLAEDAP WKKIQQNTFT RWCNEHLKCV
     SKRIANLQTD LSDGLRLIAL LEVLSQKKMH RKHNQRPTFR QMQLENVSVA LEFLDRESIK
     LVSIDSKAIV DGNLKLILGL IWTLILHYSI SMPMWDEEED EEAKKQTPKQ RLLGWIQNKL
     PQLPITNFSR DWQSGRALGA LVDSCAPGLC PDWDSWDASK PVTNAREAMQ QADDWLGIPQ
     VITPEEIVDP NVDEHSVMTY LSQFPKAKLK PGAPLRPKLN PKKARAYGPG IEPTGNMVKK
     RAEFTVETRS AGQGEVLVYV EDPAGHQEEA KVTANNDKNR TFSVWYVPEV TGTHKVTVLF
     AGQHIAKSPF EVYVDKSQGD ASKVTAQGPG LEPSGNIANK TTYFEIFTAG AGTGEVEVVI
     QDPMGQKGTV EPQLEARGDS TYRCSYQPTM EGVHTVHVTF AGVPIPRSPY TVTVGQACNP
     SACRAVGRGL QPKGVRVKET ADFKVYTKGA GSGELKVTVK GPKGEERVKQ KDLGDGVYGF
     EYYPMVPGTY IVTITWGGQN IGRSPFEVKV GTECGNQKVR AWGPGLEGGV VGKSADFVVE
     AIGDDVGTLG FSVEGPSQAK IECDDKGDGS CDVRYWPQEA GEYAVHVLCN SEDIRLSPFM
     ADIRDAPQDF HPDRVKARGP GLEKTGVAVN KPAEFTVDAK HGGKAPLRVQ VQDNEGCPVE
     ALVKDNGNGT YSCSYVPRKP VKHTAMVSWG GVSIPNSPFR VNVGAGSHPN KVKVYGPGVA
     KTGLKAHEPT YFTVDCAEAG QGDVSIGIKC APGVVGPAEA DIDFDIIRND NDTFTVKYTP
     RGAGSYTIMV LFADQATPTS PIRVKVEPSH DASKVKAEGP GLSRTGVELG KPTHFTVNAK
     AAGKGKLDVQ FSGLTKGDAV RDVDIIDHHD NTYTVKYTPV QQGPVGVNVT YGGDPIPKSP
     FSVAVSPSLD LSKIKVSGLG EKVDVGKDQE FTVKSKGAGG QGKVASKIVG PSGAAVPCKV
     EPGLGADNSV VRFLPREEGP YEVEVTYDGV PVPGSPFPLE AVAPTKPSKV KAFGPGLQGG
     SAGSPARFTI DTKGAGTGGL GLTVEGPCEA QLECLDNGDG TCSVSYVPTE PGDYNINILF
     ADTHIPGSPF KAHVVPCFDA SKVKCSGPGL ERATAGEVGQ FQVDCSSAGS AELTIEICSE
     AGLPAEVYIQ DHGDGTHTIT YIPLCPGAYT VTIKYGGQPV PNFPSKLQVE PAVDTSGVQC
     YGPGIEGQGV FREATTEFSV DARALTQTGG PHVKARVANP SGNLTETYVQ DRGDGMYKVE
     YTPYEEGLHS VDVTYDGSPV PSSPFQVPVT EGCDPSRVRV HGPGIQSGTT NKPNKFTVET
     RGAGTGGLGL AVEGPSEAKM SCMDNKDGSC SVEYIPYEAG TYSLNVTYGG HQVPGSPFKV
     PVHDVTDASK VKCSGPGLSP GMVRANLPQS FQVDTSKAGV APLQVKVQGP KGLVEPVDVV
     DNADGTQTVN YVPSREGPYS ISVLYGDEEV PRSPFKVKVL PTHDASKVKA SGPGLNTTGV
     PASLPVEFTI DAKDAGEGLL AVQITDPEGK PKKTHIQDNH DGTYTVAYVP DVTGRYTILI
     KYGGDEIPFS PYRVRAVPTG DASKCTVTVS IGGHGLGAGI GPTIQIGEET VITVDTKAAG
     KGKVTCTVCT PDGSEVDVDV VENEDGTFDI FYTAPQPGKY VICVRFGGEH VPNSPFQVTA
     LAGDQPSVQP PLRSQQLAPQ YTYAQGGQQT WAPERPLVGV NGLDVTSLRP FDLVIPFTIK
     KGEITGEVRM PSGKVAQPTI TDNKDGTVTV RYAPSEAGLH EMDIRYDNMH IPGSPLQFYV
     DYVNCGHVTA YGPGLTHGVV NKPATFTVNT KDAGEGGLSL AIEGPSKAEI SCTDNQDGTC
     SVSYLPVLPG DYSILVKYNE QHVPGSPFTA RVTGDDSMRM SHLKVGSAAD IPINISETDL
     SLLTATVVPP SGREEPCLLK RLRNGHVGIS FVPKETGEHL VHVKKNGQHV ASSPIPVVIS
     QSEIGDASRV RVSGQGLHEG HTFEPAEFII DTRDAGYGGL SLSIEGPSKV DINTEDLEDG
     TCRVTYCPTE PGNYIINIKF ADQHVPGSPF SVKVTGEGRV KESITRRRRA PSVANVGSHC
     DLSLKIPEIS IQDMTAQVTS PSGKTHEAEI VEGENHTYCI RFVPAEMGTH TVSVKYKGQH
     VPGSPFQFTV GPLGEGGAHK VRAGGPGLER AEAGVPAEFS IWTREAGAGG LAIAVEGPSK
     AEISFEDRKD GSCGVAYVVQ EPGDYEVSVK FNEEHIPDSP FVVPVASPSG DARRLTVSSL
     QESGLKVNQP ASFAVSLNGA KGAIDAKVHS PSGALEECYV TEIDQDKYAV RFIPRENGVY
     LIDVKFNGTH IPGSPFKIRV GEPGHGGDPG LVSAYGAGLE GGVTGNPAEF VVNTSNAGAG
     ALSVTIDGPS KVKMDCQECP EGYRVTYTPM APGSYLISIK YGGPYHIGGS PFKAKVTGPR
     LVSNHSLHET SSVFVDSLTK ATCAPQHGAP GPGPADASKV VAKGLGLSKA YVGQKSSFTV
     DCSKAGNNML LVGVHGPRTP CEEILVKHVG SRLYSVSYLL KDKGEYTLVV KWGDEHIPGS
     PYRVVVP
//
